Q4 2021 13F Holders as of 31 Dec 2021
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
107,809,066
-
Total 13F shares
-
64,197,108
-
Share change
-
+1,822,742
-
Total reported value
-
$7,594,973,150
-
Put/Call ratio
-
119%
-
Price per share
-
$118.24
-
Number of holders
-
361
-
Value change
-
+$200,734,926
-
Number of buys
-
160
-
Number of sells
-
167
Institutional Holders of Intellia Therapeutics, Inc. - Common Stock, par value $0.0001 per share (NTLA) as of Q4 2021
As of 31 Dec 2021,
Intellia Therapeutics, Inc. - Common Stock, par value $0.0001 per share (NTLA) was held by
361 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
64,197,108 shares.
The largest 10 holders included
ARK Investment Management LLC, VANGUARD GROUP INC, BlackRock Inc., FMR LLC, Nikko Asset Management Americas, Inc., Sumitomo Mitsui Trust Holdings, Inc., PRICE T ROWE ASSOCIATES INC /MD/, STATE STREET CORP, VIKING GLOBAL INVESTORS LP, and MORGAN STANLEY.
This page lists
361
institutional shareholders reporting positions in this security
for the Q4 2021 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.